Navigation Links
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Date:4/15/2008

class," said Joseph C. Gathe, Jr., M.D., F.A.C.P., clinical instructor, department of internal medicine, Baylor College of Medicine, Houston, and lead investigator for the study. "This treatment strategy could also prove beneficial for the growing number of patients who already have primary resistance to NRTIs prior to any treatment."

In previous studies in treatment-experienced HIV-infected patients, vicriviroc in combination with an optimized ritonavir-boosted PI-containing regimen demonstrated potent and sustained viral suppression through 48 weeks of treatment.(4, 5)

The standard of care for treatment-naive HIV-infected individuals is to combine three drugs from two classes to initiate antiretroviral therapy. The combinations characteristically use two NRTIs with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted PI.(6) While these combinations have been demonstrated to be highly effective, long-term tolerance may be limited by the toxicity specifically associated with nucleosides, which can include neuropathy, myopathy, renal toxicity, hepatic steatosis, lactic acidosis, bone marrow suppression, fat atrophy and, with certain agents, increased risk of myocardial infarction.(7-9)

"As a next-generation HIV entry inhibitor, vicriviroc has the potential to benefit a broad range of patients by offering potent and sustained viral suppression, and a single once-daily dose for use in combination with other antiretroviral agents," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "CCR5 antagonists such as vicriviroc have a novel mechanism of action in fighting HIV, and may play a unique role as physicians seek to construct new regimens to meet the specific needs of their patients, whether they are starting treatment or have been treated with several different combinations over a period of time."

About the Phase II Naive Study

This rando
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Schering-Plough Reports Top-Line Results of the IDEAL Study
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... 17, 2014   MedeAnalytics today unveils ... brings complete visibility to a provider,s "mid-cycle" to ... reimbursement landscape. Powered by the industry,s leading big ... critical point between patient access and the business ... will improve revenue capture, minimize audit risk and ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Oct. 31, 2011 Covance Inc. (NYSE: ... ranked first, by a wide margin, in an independent ... trials. The majority (54 percent) of the study participants ... central laboratory, with investigators citing Covance three times more ...
... InterMune, Inc. (NASDAQ: ITMN ) today ... Shire plc, has been appointed to InterMune,s Board of ... on meeting the needs of the specialist physician. ... a leading global biopharmaceutical company with expertise in the ...
Cached Medicine Technology:Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 2Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 3InterMune Appoints Angus C. Russell to Board of Directors 2InterMune Appoints Angus C. Russell to Board of Directors 3
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... The Food and Drug Administration (FDA) has ... consider: , 1. The appropriate indicated ... 2. The potential for adverse cardiovascular outcomes associated ... ongoing, an informally-organized litigation group subcommittee prepared a presentation ... therapy. Among others, ZKB attorney Michelle L. Kranz and ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 ... University, revealed 12 companies raising rounds of funding at ... a few hundred investors and media, was the first ... headquarters located next to the university. The presentations were ... volunteers, adjacent to StartX-QB3 Labs, a 2,000 square foot ...
(Date:9/17/2014)... Cadiz Laser Spa offers the latest, most ... throughout Central Texas. The newest addition to their ... Using the revolutionary Rejuvapen micro-needling device Cadiz Laser ... a wide variety of skin issues. , The ... Spa is currently offering a special package through ...
(Date:9/17/2014)... News) -- Present-day Europeans are the descendants of ... to a new study. Previous research ... early European farmers. But, a new genetic analysis ... the descendants of Ancient North Eurasians. Nearly all ... ancestral group, researchers from Harvard Medical School said. ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3
... in 2007, Blue Cross Blue Shield of Georgia (BCBSGa) announced ... clinical psychologists by approximately 19%. This new rate is ... home handyman per hour. However, unlike your mechanic, BCBSGa ... were paid 10 years ago by BCBSGa. In 1998 ...
... Care innovations and opportunities attract attendees from more than ... 6th Annual World Health Care Congress April 14-16, 2009, ... Muhammad Yunus of the Grameen Bank and a delegation ... from more than a dozen other countries at the ...
... Improve Community SafetyJEFFERSON CITY, Mo. , April 7 ... and Parole has launched a new alcohol monitoring Pilot ... alcohol monitoring on the management of the state,s alcohol-fueled ... offenders with a documented history of alcohol abuse and ...
... WASHINGTON, April 7 Dr. Michael J. Kussman, the Under ... today announced his intention to retire from federal service by ... who attained the rank of brigadier general while in the ... for Health since 2007, Dr. Kussman has directed a health ...
... connection between out-of-pocket expenses for people contending with ... antidepressant treatment. , Dr. Carolyn Dewa, head of ... at the Centre of Addiction and Mental Health ... of money spent on medication before a disability ...
... provider of Microsoft Dynamics CRM ... live, Resurrection Health Care experienced a 50% increase in ... health care provider, is a family of health care ... services, behavioral health services and numerous outpatient centers. , ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Georgia Is Skimping on Mental Health Care, Says Georgia Psychological Association 2Health News:Blue Cross Blue Shield of Georgia Is Skimping on Mental Health Care, Says Georgia Psychological Association 3Health News:Nobel Prize Winner Professor Muhammad Yunus Leading Delegation From Bangladesh to World Health Care Congress to Advance Affordable Health Care Innovations 2Health News:Nobel Prize Winner Professor Muhammad Yunus Leading Delegation From Bangladesh to World Health Care Congress to Advance Affordable Health Care Innovations 3Health News:Nobel Prize Winner Professor Muhammad Yunus Leading Delegation From Bangladesh to World Health Care Congress to Advance Affordable Health Care Innovations 4Health News:Missouri DOC Conducting Pilot of 24/7 Alcohol Anklets 2Health News:Missouri DOC Conducting Pilot of 24/7 Alcohol Anklets 3Health News:Michael J. Kussman, VA Under Secretary for Health, to Retire 2Health News:When physical and mental health problems co-occur and money gets tight, which prescriptions go unfilled? 2Health News:Resurrection Health Care Increases Sales Productivity by 50% Since Implementing Microsoft Dynamics CRM 2Health News:Resurrection Health Care Increases Sales Productivity by 50% Since Implementing Microsoft Dynamics CRM 3
This 100 µL is the equivalent to the "Universal Blue" tips and fits virtually every manufacturer's 1000 µL Pipettor....
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
Volume range 0.2-10 l. Designed for pipetting micro-sized drops. Ideal for use with micro volume Finnpipettes....
Conducting disposable tips....
Medicine Products: